OABI
OmniAb, Inc. NASDAQ Listed Sep 30, 2021$2.32
-0.85%
vs $2.34
Mkt Cap $263.6M
52w Low $1.36
70.6% of range
52w High $2.72
50d MA $1.98
200d MA $1.80
P/E (TTM)
-5.0x
EV/EBITDA
—
P/B
1.0x
Debt/Equity
0.1x
ROE
-24.3%
P/FCF
-7.1x
RSI (14)
40.40
ATR (14)
$0.20
Beta
0.87
50d MA
$1.98
200d MA
$1.80
Avg Volume
879.9K
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
CIK (SEC)
Phone
510 250 7800
5980 Horton Street · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.10 | -0.06 | +40.0% | 1.47 | +4.8% | +12.9% | +0.6% | +10.8% | +8.6% | +9.0% | — |
| Mar 4, 2026 | AMC | -0.08 | -0.11 | -37.5% | 1.81 | +0.0% | +10.5% | -5.5% | +3.2% | +2.1% | -1.5% | — |
| Nov 4, 2025 | AMC | -0.14 | -0.14 | -2.9% | 1.48 | -2.7% | -3.4% | -3.5% | +0.0% | +8.0% | +8.1% | — |
| Aug 6, 2025 | AMC | -0.14 | -0.15 | -7.1% | 1.93 | -1.0% | -2.6% | +4.8% | -0.5% | +0.0% | +4.6% | — |
| May 8, 2025 | AMC | -0.17 | -0.17 | +0.0% | 1.57 | -0.6% | -8.3% | -0.7% | -2.1% | +8.6% | +2.0% | — |
| Mar 18, 2025 | AMC | -0.13 | -0.12 | +7.7% | 3.19 | -4.4% | -20.4% | -10.6% | +11.5% | +0.4% | -3.9% | — |
| Nov 12, 2024 | AMC | -0.14 | -0.16 | -14.3% | 4.49 | -10.9% | -9.4% | +0.0% | -4.7% | -4.1% | +3.2% | — |
| Aug 8, 2024 | AMC | -0.18 | -0.13 | +27.8% | 4.29 | +5.4% | -1.2% | -2.6% | +3.1% | -3.5% | +2.7% | — |
| May 9, 2024 | AMC | -0.17 | -0.19 | -11.8% | 4.57 | -3.5% | +2.4% | -4.3% | +0.4% | +0.9% | +0.2% | — |
| Mar 20, 2024 | AMC | -0.17 | -0.14 | +17.6% | 5.42 | +5.5% | -5.2% | -0.2% | +3.5% | -2.3% | +3.9% | — |
| Nov 9, 2023 | AMC | -0.14 | -0.16 | -14.3% | 4.36 | +4.4% | -2.8% | +4.5% | +6.3% | -1.5% | -4.1% | — |
| Aug 10, 2023 | AMC | -0.11 | -0.15 | -36.4% | 5.78 | +0.0% | -5.5% | -0.2% | +2.2% | +6.5% | -1.3% | — |
| May 11, 2023 | AMC | 0.05 | -0.06 | -220.0% | 3.23 | +5.3% | +8.4% | +0.3% | +9.1% | +1.3% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $1.93 | $1.91 | -1.0% | -2.6% | +4.8% | -0.5% | +0.0% | +4.6% |
| May 12 | Benchmark | Maintains | Buy → Buy | — | $1.44 | $1.48 | +2.8% | -0.7% | -2.1% | +8.6% | +2.0% | +1.9% |
| Mar 27 | RBC Capital | Maintains | Outperform → Outperform | — | $2.43 | $2.42 | -0.4% | +1.6% | -2.0% | -0.8% | -5.0% | +1.3% |
| Mar 20 | Benchmark | Maintains | Buy → Buy | — | $2.54 | $2.55 | +0.4% | -10.6% | +11.5% | +0.4% | -3.9% | -0.4% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.19 | $3.05 | -4.4% | -20.4% | -10.6% | +11.5% | +0.4% | -3.9% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.07 | $4.07 | +0.0% | +0.0% | -4.7% | -4.1% | +3.2% | +1.6% |
| Nov 14 | Benchmark | Maintains | Buy → Buy | — | $4.07 | $4.07 | +0.0% | +0.0% | -4.7% | -4.1% | +3.2% | +1.6% |
| Aug 19 | Benchmark | Maintains | Buy → Buy | — | $4.18 | $4.17 | -0.2% | +0.7% | -1.0% | +0.0% | -2.4% | +5.2% |
| Aug 16 | RBC Capital | Maintains | Outperform → Outperform | — | $4.22 | $4.22 | +0.0% | -0.9% | +0.7% | -1.0% | +0.0% | -2.4% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.24 | $4.25 | +0.2% | -2.6% | +3.1% | -3.5% | +2.7% | -0.9% |
| May 14 | Benchmark | Maintains | Buy → Buy | — | $4.48 | $4.52 | +0.9% | +0.4% | +0.9% | +0.2% | -2.2% | -1.3% |
| Mar 26 | Truist | Maintains | Buy → Buy | — | $5.31 | $5.34 | +0.6% | -2.3% | +3.9% | +0.6% | -1.1% | -1.5% |
| Mar 22 | Benchmark | Maintains | Buy → Buy | — | $5.14 | $5.14 | +0.0% | -0.2% | +3.5% | -2.3% | +3.9% | +0.6% |
| Mar 21 | RBC Capital | Maintains | Outperform → Outperform | — | $5.42 | $5.72 | +5.5% | -5.2% | -0.2% | +3.5% | -2.3% | +3.9% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.42 | $5.72 | +5.5% | -5.2% | -0.2% | +3.5% | -2.3% | +3.9% |
| Nov 14 | Benchmark | Maintains | Buy → Buy | — | $4.43 | $4.56 | +2.9% | +6.3% | -1.5% | -4.1% | +0.0% | +1.6% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.78 | $5.78 | +0.0% | -5.5% | -0.2% | +2.2% | +6.5% | -1.3% |
| May 12 | Benchmark | Maintains | Buy → Buy | — | $3.23 | $3.40 | +5.3% | +8.4% | +0.3% | +9.1% | +1.3% | +1.0% |
| Apr 21 | Benchmark | Maintains | Buy → Buy | — | $3.59 | $3.60 | +0.3% | +8.1% | -6.2% | -4.4% | +0.6% | -0.6% |
| Apr 13 | Craig-Hallum | Maintains | Buy → Buy | — | $3.81 | $3.93 | +3.1% | +0.5% | -1.0% | -2.9% | -4.9% | +2.6% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.51 | $4.12 | +17.4% | +4.8% | -0.5% | +1.1% | +0.0% | +1.4% |
| Feb 22 | TD Cowen | Maintains | Outperform → Outperform | — | $3.86 | $4.01 | +3.9% | +2.3% | +0.0% | +0.5% | +0.5% | +4.5% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.88 | $4.15 | +7.1% | -1.5% | +0.4% | -0.8% | -2.6% | -0.5% |
| Dec 20 | Truist | Maintains | Buy → Buy | — | $3.24 | $3.28 | +1.2% | +1.9% | +17.0% | -5.7% | -2.2% | +4.2% |
| Dec 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $3.46 | $3.67 | +6.1% | +0.9% | -7.2% | +1.9% | +17.0% | -5.7% |
| Nov 29 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.88 | $2.93 | +1.7% | -1.4% | +24.6% | -5.4% | +18.5% | -1.8% |
| Nov 28 | Stifel | Maintains | Buy → Buy | — | $2.61 | $2.68 | +2.7% | +10.3% | -1.4% | +24.6% | -5.4% | +18.5% |
No insider trades available.
8-K
OmniAb, Inc. -- 8-K Filing
I cannot provide a meaningful analysis of this filing because the summary contains only generic technical metadata about XBRL tagging requirements rather than actual business information about OmniAb's events or transactions.
Jun 18
8-K
OmniAb, Inc. -- 8-K Filing
OmniAb reported its Q4 and full-year 2025 financial results, including operational updates and partner program progress that may impact future revenue growth and strategic partnerships.
Mar 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 3,993,652 | $6M | New | Mar 2026 |
| 2 | Rice Hall James & Associates, Llc | 2,401,088 | $4M | — | Dec 2025 |
| 3 | Private Management Group Inc | 2,429,166 | $4M | — | Mar 2026 |
| 4 | Morgan Stanley | 779,374 | $1M | Reduced | Dec 2025 |
| 5 | Vanguard Portfolio Management Llc | 903,799 | $1M | New | Mar 2026 |
| 6 | Northern Trust Corp | 880,895 | $1M | Added | Mar 2026 |
| 7 | Adar1 Capital Management, Llc | 705,190 | $1M | New | Mar 2026 |
| 8 | Nomura Holdings Inc | 705,048 | $1M | Added | Mar 2026 |
| 9 | Nuveen, Llc | 623,876 | $979K | Reduced | Mar 2026 |
| 10 | Two Sigma Investments, Lp | 512,741 | $805K | Added | Mar 2026 |
| 11 | Millennium Management | 523,918 | $630K | Reduced | Mar 2026 |
| 12 | D.e. Shaw & Co | 380,254 | $597K | Reduced | Mar 2026 |
| 13 | Eversource Wealth Advisors, Llc | 11,020 | $550K | Added | Mar 2026 |
| 14 | Bank Of New York Mellon Corp | 274,451 | $431K | Added | Mar 2026 |
| 15 | Renaissance Technologies Llc | 269,600 | $423K | Added | Mar 2026 |
| 16 | Tls Advisors Llc | 250,185 | $393K | Added | Mar 2026 |
| 17 | Citadel Advisors Llc | 228,684 | $359K | Reduced | Mar 2026 |
| 18 | Arbiter Partners Capital Management Llc | 192,585 | $302K | — | Mar 2026 |
| 19 | Fmr Llc | 189,536 | $298K | Reduced | Mar 2026 |
| 20 | Stonepine Capital Management, Llc | 164,045 | $258K | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$263.6M
Enterprise Value
$209.6M
P/E (TTM)
-5.04x
Forward P/E
—
PEG Ratio
0.49x
P/B
0.99x
P/S
9.12x
P/FCF
-7.12x
EV/EBITDA
—
Shares Out
113.6M
Financials (TTM)
Revenue
$28.9M
Net Income
-$54.3M
EBITDA
-$33.8M
Free Cash Flow
-$37.0M
Op Cash Flow
-$36.5M
EPS Basic
$-0.57
EPS Diluted
$-0.46
EPS Forward
$-0.38
Gross Margin
35.4%
Op Margin
-200.3%
Net Margin
-187.7%
Balance Sheet
Total Assets
$300.9M
Total Liab.
$33.9M
Total Equity
$267.0M
Cash
$54.0M
LT Debt
$0
Book Value/Sh
$2.35
Debt/Equity
0.08x
Current Ratio
4.02
Quick Ratio
4.02
Returns & Growth
ROE
-24.3%
ROA
-21.5%
ROIC
-24.2%
Rev Growth YoY
-29.3%
EPS Growth YoY
+6.6%
Price Returns
2W
+23.3%
1M
+94.2%
3M
+57.0%
6M
+49.2%
12M
+112.6%
Technicals
52W High
$2.72
52W Low
$1.36
50d MA
$1.98
200d MA
$1.80
RSI (14)
40.40
ATR (14)
$0.20
Beta
0.87
Avg Volume
880K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$4.00
High
$4.00
Low
$4.00
Median
$4.00
Data updated apr 26, 2026 4:43pm
· Source: financialmodelingprep.com